---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-283649"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:22:29.390461+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alaunos reports Q3 net loss $8.9M; first objective response in TCR-T Library trial

## Summary
- Q3 2022 net loss $8.9M ($0.04/sh) vs $22.7M ($0.11/sh) in Q3 2021; revenue $2.9M from darinaparsin milestone.
- First patient with NSCLC achieved >50% tumor regression at 12 weeks with Sleeping Beauty TCR-T cells targeting KRAS G12D.
- TCR-T cell persistence observed: ~30% of blood T-cells at 24 weeks in patient 1; manageable safety, no ICANS.
- Manufacturing capacity doubled to produce two products simultaneously; IND amendment in 4Q22 to add two TCRs and switch to cryopreserved process (26 days vs 30).
- Cash $37.8M plus restricted cash $13.9M; operating cash burn $6.1M in Q3 2022, down 36% YoY.

## SEC filing metadata
- accession: 0001193125-22-283649
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312522283649/0001193125-22-283649-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312522283649/d411392d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-283649
- JSON: https://secwatch.observer/filing/0001193125-22-283649.json
- Plain text: https://secwatch.observer/filing/0001193125-22-283649.txt

## Key facts
- Earnings Releases
  Alaunos Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $2.9 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $2.9 million
  - Result: reported results
  source text: Collaboration revenue was $2.9 million for the third quarter of 2022, compared to $0.4 million for the third quarter of 2021, an increase of 631%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312522283649/0001193125-22-283649-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.